This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services (HHS). The $128,312.76 cost-plus-fixed-fee contract was awarded to Southern Research Institute, a non-profit organization that provides research and development services, to develop new assays for HIV therapeutics and topical microbicides. The contract does not have a set-aside designation. Southern Research Institute...
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the U.S. Department of Health and Human Services, to Accelevir Diagnostics LLC, a woman-owned small business. The contract, valued at $299,975.00, is for the company to adapt its Intact Proviral DNA Assay (IPDA) to measure latent HIV-1 for individuals with the CRF-1_AE genetic subtype of the virus. This contract is part of NIAID's Small Business Innovation Research (SBIR)...
This is a $1,500,000.00 Small Business Innovation Research (SBIR) Phase II contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a division of the Department of Health and Human Services, to Cure Systems LLC, a self-certified small disadvantaged business located in Newton, Massachusetts. The contract is for the research and development of "Vector-Based Delivery of HIV Broadly Neutralizing Antibodies," a specialized approach to developing advanced...
This is a Cost Plus Fixed Fee delivery order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services (HHS), to Southern Research Institute, a non-profit organization. The contract, which has a ceiling value of $516,234.16, is for the identification of anti-HIV therapeutics and topical microbicides. It falls under NIAID's In Vitro Testing Resource for HIV Therapeutics and Topical Microbicides program. The contract...
This is a $299,988 Firm Fixed Price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Zymeron Corporation, a minority-owned small business. The contract is for the development of novel, low-cost, real-time point-of-care (POC) assays for HIV viral load monitoring, HIV drug resistance monitoring, and pharmacological adherence monitoring. This contract was awarded under the Small Business Innovation...
The U.S. National Institute of Allergy and Infectious Diseases (NIAID) awarded a $306,206.00 firm fixed-price Small Business Innovation Research (SBIR) Phase I contract to Intuitive Biosciences Inc., a small disadvantaged business, to develop "THE EV-HIV ASSAY, A POINT-OF-CARE LATERAL FLOW IMMUNOASSAY TO ACCURATELY IDENTIFY HIV INFECTION FROM BLOOD-BASED EXTRACELLULAR VESICLES." This contract is linked to a broader SBIR solicitation issued by the NIAID and Centers for Disease Control...
This federal contract award, valued at $499,879.67, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services (HHS), to Southern Research Institute, a non-profit research organization. The contract is for the identification of lead compounds to inhibit HIV, as part of NIAID's broader "In Vitro Testing Resource for HIV Therapeutics and Topical Microbicides" program. The contract is a Delivery Order...
This is a $1,648,645.00 Firm Fixed Price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, to Cell Microsystems Inc. under the Small Business Innovation Research (SBIR) Phase II program. The purpose of this contract is to focus on developing a T-cell activation protocol consistent with reporter cell viability, creating a proprietary reporter cell line, and gathering and benchmarking...
The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases awarded a Small Business Innovation Research (SBIR) Program Phase II contract to Aldatu Biosciences, Inc. to develop an assay to detect minor populations of resistant HIV variants in blood specimens from infected individuals with viral loads above 1,000 copies/mL. The firm-fixed-price contract, valued at $2,980,467.00, was awarded on July 30, 2018 with a...
The federal contract award, HHSN272201600008I|HHSN27200001, was granted by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to Advanced Bioscience Laboratories, Inc. (ABL), a for-profit manufacturer of goods. The contract is for $4,669,061.95 and is for quality assurance/quality control (QA/QC) services in support of the NIAID's Comprehensive Resources for HIV Microbicides and Biomedical Prevention...